A Phase 4 interventional study of Doxycycline hyclate (Doryx) and Doxycycline hyclate in Acne Vulgaris, sponsored by Warner Chilcott. Completed at 4 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-04-20.
Sponsored by Warner Chilcott (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing doxycycline in Acne Vulgaris — 2 open to participants now, 3 under way, none of them phase 3. Doxycycline · Acne Vulgaris.
Among the 12 studies testing doxycycline in Acne Vulgaris, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 4, and was the 3rd registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →2 of the 12 studies testing doxycycline in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Sites in Bangladesh
Ages 18+
By country, each count listing its studies:
Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 2 · Phase 4 6
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 47 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Warner Chilcott, one of the names counted as AbbVie. Under that name alone:
Warner Chilcott is the lead sponsor of 58 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
17 studies in Acne Vulgaris by AbbVie: none open now, none under way, none of them phase 3. Of 15 finished, 12 (80%) have results posted.
Among the 17 studies in Acne Vulgaris by AbbVie, this one is the 10th largest by enrollment, is one of 4 that started in 2008, is one of 7 in phase 4, and was the 4th registered.
AbbVie’s Acne Vulgaris studies by the year they started, since 2005.
2 of the studies testing doxycycline in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT07544251Integrative Skin Science and ResearchComparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne. | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing doxycycline in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 17 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, multi-center, open label, active-comparator study to compare the efficacy and tolerability of Doryx Delayed Release Tablets to doxycycline hyclate in patients with moderate to severe acne vulgaris.
Efficacy of Doryx Delayed Release Tablets to doxycycline hyclate will be assessed using an Investigator's Global Assessment (IGA) score and the absolute change from baseline to 12 weeks in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. Additionally, the absolute change from baseline to 12 weeks in non-inflammatory lesions count of Doryx Delayed Release Tablets compared to doxycycline hyclate will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Doxycycline hyclate (Doryx)
Drug: Doxycycline hyclate
150mg/day, oral, delayed release tablets
Also known as: Doryx
100 mg/day, oral, tablets, immediate release
Successful Outcome According to Investigator's Global Assessment (IGA)
The Investigator's Global Assessment (IGA) was performed at baseline and at 12 weeks. The IGA score is based on a 5-point acne severity scale from zero (clear) to 4 (severe). Successful outcome is at least a 2-point reduction in IGA score from baseline to 12 weeks.
Time frame: baseline and 12 weeks
Change From Baseline in Inflammatory Acne Lesion Count on the Face at 12 Weeks
Acne lesions fall into 2 groups: inflammatory and non-inflammatory. The number of inflammatory acne lesions on the face was measured at baseline and after 12 weeks. The difference (change) was calculated.
Time frame: baseline and 12 weeks
Change From Baseline in Non-inflammatory Acne Lesion Count on the Face at 12 Weeks
Acne lesions fall into 2 groups: inflammatory and non-inflammatory. The number of non-inflammatory acne lesions on the face was measured at baseline and after 12 weeks. The difference (change) was calculated.
Time frame: baseline and 12 weeks
| Milestone | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets |
|---|---|---|
| Started | 48 | 45 |
| Completed | 41 | 42 |
| Not completed | 7 | 3 |
The Investigator's Global Assessment (IGA) was performed at baseline and at 12 weeks. The IGA score is based on a 5-point acne severity scale from zero (clear) to 4 (severe). Successful outcome is at least a 2-point reduction in IGA score from baseline to 12 weeks.
| participants | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets |
|---|---|---|
| Successful Outcome According to Investigator's Global Assessment (IGA) | 18 | 19 |
Acne lesions fall into 2 groups: inflammatory and non-inflammatory. The number of non-inflammatory acne lesions on the face was measured at baseline and after 12 weeks. The difference (change) was calculated.
| Acne lesion count | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets |
|---|---|---|
| Change From Baseline in Non-inflammatory Acne Lesion Count on the Face at 12 Weeks | 23.2 ± 19.3 | 27.6 ± 20.0 |
Acne lesions fall into 2 groups: inflammatory and non-inflammatory. The number of inflammatory acne lesions on the face was measured at baseline and after 12 weeks. The difference (change) was calculated.
| acne lesion count | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets |
|---|---|---|
| Change From Baseline in Inflammatory Acne Lesion Count on the Face at 12 Weeks | 21.8 ± 13.8 | 26.6 ± 12.5 |
Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doxycycline Hyclate (Doryx) Delayed-release Tablets | — | 1/48 (2.1%) | 10/48 (20.8%) |
| Doxycycline Hyclate Immediate-release Tablets | — | 1/45 (2.2%) | 11/45 (24.4%) |
| Event | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets |
|---|---|---|
| Ruptured ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/48 | 1/45 |
| Acute cholecystitisHepatobiliary disorders | 1/48 | 0/45 |
| Event | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets |
|---|---|---|
| HeadacheNervous system disorders | 7/48 | 3/45 |
| NauseaGastrointestinal disorders | 0/48 | 4/45 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 0/48 | 3/45 |
| SunburnInjury, poisoning and procedural complications | 3/48 | 1/45 |
| Age, Categorical(Participants) | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets | Total |
|---|---|---|---|
| <=18 years | 28 | 21 | 49 |
| Between 18 and 65 years | 20 | 24 | 44 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets | Total |
|---|---|---|---|
| Mean | 19.3 ± 5.8 | 20.9 ± 7.9 | 20.1 ± 6.9 |
| Sex: Female, Male(Participants) | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets | Total |
|---|---|---|---|
| Female | 17 | 16 | 33 |
| Male | 31 | 29 | 60 |
| Region of Enrollment(participants) | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets | Total |
|---|---|---|---|
| United States | 48 | 45 | 93 |
| Ethnic Origin(participants) | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets | Total |
|---|---|---|---|
| Hispanic | 27 | 26 | 53 |
| Not of Hispanic origin | 21 | 19 | 40 |
| Race(participants) | Doxycycline Hyclate (Doryx) Delayed-release Tablets | Doxycycline Hyclate Immediate-release Tablets | Total |
|---|---|---|---|
| Asian or Pacific Islander | 0 | 1 | 1 |
| Black | 3 | 5 | 8 |
| Caucasian | 22 | 18 | 40 |
| Other | 23 | 21 | 44 |
The record gives a start of Mar 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxycycline